Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) - Trial NCT05823402
Access comprehensive clinical trial information for NCT05823402 through Pure Global AI's free database. This phase not specified trial is sponsored by BAMF Health and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
BAMF Health
Timeline & Enrollment
N/A
May 01, 2023
Oct 31, 2024
Primary Outcome
Dosimetry Method
Summary
The SPECTacular study will enroll patients who are already undergoing a FDA approved
 PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive
 5 additional SPECT/CT scans to investigate the limits of agreement between dosimetry
 (absorbed radiation dose) approximation methods and dosimetry using the triexponential
 fitting method.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05823402
Non-Device Trial